Acute Coronary Syndrome in Patients with Atrial Fibrillation: Which is the Benefit/Risk Profile of Triple Antithrombotic Therapy?
Circulation. 2012 Aug 6;
Authors: Maggioni AP
Dual antiplatelet therapy is the recommended treatment for all patients with an acute coronary syndrome treated or not with an invasive procedure(1-4). Several trials testing clopidogrel(5-7) or new antiplatelet agents(8,9) clearly showed that the addition of a thyenopiridine to aspirin is associated with a significant improvement of patients' outcomes. Further, even in the case of elective percutaneous coronary procedures, the use of dual antiplatelet therapy is recommended for a medium-long period of time after the procedure(2,4,10). (SELECT FULL TEXT TO CONTINUE).
PMID: 22869840 [PubMed - as supplied by publisher]Link to Article at PubMed